American Association for Cancer Research (AACR) Annual Meeting 2026

San Diego, California, US 17 April 2026 - 22 April 2026

Post-neoadjuvant therapy ctDNA status predicts response, distant recurrence in TNBC

15 May 2026 by

In patients with early triple-negative breast cancer (TNBC), the presence of circulating tumour (ct)DNA after neoadjuvant therapy but before surgery is strongly associated with poor response and distant recurrence outcomes, according to the substudy of the NSABP B-59/GBG-96-GeparDouze trial.

15 May 2026

Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?

12 May 2026 by

Perioperative adebrelimab plus chemotherapy improves event-free survival (EFS) and major pathological response (MPR) in individuals with resectable stage II/III non-small cell lung cancer (NSCLC) in an interim analysis.

12 May 2026

Tebentafusp a ray of hope in rare eye cancer

11 May 2026 by

The 5-year data from the phase III IMCgp100-202 study demonstrate durable, long-term overall survival (OS) benefit with the novel agent tebentafusp—a first-in-class, bispecific, soluble T-cell receptor (TCR) therapeutic—in individuals with previously untreated metastatic uveal melanoma (UM).

11 May 2026

Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases

05 May 2026 by

Treatment with ipilimumab plus nivolumab improves long-term survival in melanoma patients with asymptomatic brain metastases, according to the results of the NIBIT-M2 trial presented at AACR 2026.

05 May 2026